The most common symptoms are upper abdominal complaints, anaemia and weight loss, but in the majority of cases gastric cancer is asymptomatic in its early stages.
The incidence of gastric cancer has declined over the last few decades. However, the proportion of gastric cardia carcinomas has increased.
Geographic variation exists in the incidence of gastric cancer, the rates being highest in Asia, Southern and Eastern Europe and parts of South America and lowest in North America, Northern Europe and Africa. Worldwide, there were almost 970 000 new cases in 2022, with about 660 000 deaths http://gco.iarc.who.int/media/globocan/factsheets/cancers/7-stomach-fact-sheet.pdf.
Aetiology
Environmental factors are thought to play a central role in the development of gastric cancer. Helicobacter pylori infection is the most important environmental factor.
Infection by Helicobacter causes inflammation of the gastric mucosa which, in some patients, results in chronic atrophic gastritis. Atrophic mucosa is more likely to undergo changes that lead to cancer.
Should always be carried out if the patient has alarming symptoms Dyspepsia, and in patients over 55 years presenting with a new upper abdominal complaint
Staging is based on a whole body CT scan (and endoscopic ultrasound)
The findings of an upper abdominal ultrasound that was prompted by symptoms may potentially include ascites or liver metastasis.
No specific laboratory tests are available. It is recommended that basic blood count with platelets and liver function tests (ALT, ALP) are checked.
Treatment
Curative surgery
Distal tumours: >⅔ resection; other tumours: total gastrectomy
Some lymph nodes should be removed from the tissues surrounding the stomach during the surgery.
At least 15 lymph nodes from the surgical tissue sample should undergo analysis.
Splenectomy should only be performed if there is a high probability that the patient has lymph node metastases in the hilum of the spleen.
Certain early-stage tumours may be managed with a more minor procedure, such as endoscopic mucosal resection.
Pneumococcal, meningococcal and haemophilus vaccinations are indicated after splenectomy.
Oncological treatment combined with curative surgery
Perioperative cytotoxic chemotherapy
Perioperative cytotoxic chemotherapy (pre- and postoperatively) can be given in an attempt to improve the prognosis of gastric cancer.
The aim of preoperative treatment is to reduce the tumour mass, increase the radical resection rate and thus improve prognosis.
Chemotherapy is also better tolerated before the surgery.
The average survival time is about 1 year (see later in the text) and oncological treatment is more important than surgical treatment in a metastatic disease.
Chemotherapy improves survival compared with best symptomatic treatment.
In metastatic disease, the median life expectancy of a patient treated with chemotherapy is 12 months.
In HER2 positive disease, the addition of the anti-HER2 antibody trastuzumab to the chemotherapy regimen significantly increases survival.
The most common complications requiring treatment of advanced gastric cancer are GI tract obstruction or bleeding.
Obstruction
Palliative resection if possible (better than bypass or stenting)
Gastrojejunostomy
Endoscopic stenting
Haemorrhage
Resection if possible
The role of resection in metastatic disease with no major symptoms is unclear.
Prognosis
About 50% of gastric cancers are not diagnosed until the disease has advanced, and prognosis is therefore poor.
The 5-year survival rate is generally about 30% and after curative treatment 50%.
Follow-up
Intensive follow-up regimens have not been shown to improve prognosis.
A follow-up regimen aims to
detect possible nutritional deficits resulting from the surgery
As necessary, the patient should be referred to the care of a dietitian or a specialist physician.
identify recurrences which may be treated curatively (rarely).
Endoscopy after subtotal gastrectomy every couple of years
Imaging studies or a referral for specialist care as guided by symptoms, for example, the emergence of eating difficulties, weight loss or abdominal pain.
Need for replacement therapy
Iron deficiency is the most common cause of anaemia after gastric surgery. It can usually be corrected by oral iron products.
Megaloblastic anaemia resulting from vitamin B12 deficiency is also common. After total gastrectomy, vitamin B12 is normally administered through injections every 3 months, but also oral B12 substitutioncan be tried.
Also folate deficiency is possible after gastrectomy.